Status:
NOT_YET_RECRUITING
Using the Epitranscriptome to Diagnose and Treat Gliomas
Lead Sponsor:
Institut du Cancer de Montpellier - Val d'Aurelle
Collaborating Sponsors:
National Cancer Institute, France
Conditions:
Glioma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diffuse gliomas are among the most common tumors of the central nervous system, with high morbidity and mortality and very limited therapeutic possibilities. The diffuse glioma are characterized by si...
Detailed Description
Diffuse gliomas are among the most common tumors of the central nervous system, with high morbidity and mortality and very limited therapeutic possibilities. Diffuse gliomas are characterized by great...
Eligibility Criteria
Inclusion
- Male / female over 18 years of age,
- Surgery (tumor resection) scheduled at Montpellier University Hospital for suspected, diffuse glioma, confirmed on tissue sample: IDH mutated grade 2 glioma (excluding tumors with a focus of grade 3 or 4 glioma), IDH mutated grade 3 glioma or GBM, IDH wild-type,
- No history of treatment (surgery, radiotherapy or chemotherapy) for glioma,
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures,
- Patient has given express written informed consent prior to any study procedure,
- Patient affiliated to a French health insurance.
Exclusion
- Patients whose regular follow-up is impossible for psychological, family, social or geographical reasons,
- Patients under guardianship, curatorship or safeguard of justice,
- Pregnant and/or breast-feeding patient (information gathered from the medical file, as part of the patient's standard medical care and follow-up),
- Histo-molecular diagnosis of grade 4 IDH-mutated astrocytoma,
- For grade 2 gliomas, presence within the tumor of one or more higher-grade sites (3 or 4).
Key Trial Info
Start Date :
March 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT06575452
Start Date
March 1 2026
End Date
October 1 2028
Last Update
December 3 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Insitut Régional du Cancer de Montpellier
Montpellier, Hérault, France, 34298
2
CHU Montpellier - Hôpital St Eloi
Montpellier, France, 34090